Astra Biotech, a developer of single molecule immunodiagnostic technology based in Suzhou, has reportedly raised “tens of millions” of renminbi in a pre-Series B financing round. The round was led by Zheng Xuan Investment, with participation from BioTrack Capital, Chuangshou Equity Investment, and others. The funds will be utilized to enhance market presence in medical diagnostics, health check-ups, and medical testing systems, as well as to improve screening and diagnostic protocols for neuroblood biomarkers and support international market expansion.
Astra Biotech has established an independent single-molecule immune detection platform and is a frontrunner in the domestic market for neural and blood biomarkers. The company has formed partnerships with several leading hospitals across China.- Flcube.com
